Archive: Company News
Company News: Multiplexed Analysis of ALK, ROS1, and RET Rearrangements in Lung Cancer Enabled by the MassARRAY® System
Agena Bioscience today announced a comparative study published in Scientific Reports highlighting the use of its mass spec-based platform for transcriptome analysis of ALK, ROS1, and RET gene fusions in lung cancer.
Company News: Anergis Completes Patient Recruitment in Large-Scale ATIBAR Trial with Ultra-Fast Allergy Immunotherapy AllerT
— 421 patients randomized at 38 European trial centers
— Top-line results expected in Q3, 2017
Anergis, a company developing proprietary ultra-fast allergy immunotherapy, announced today that it has completed patient recruitment in the ATIBAR trial, a Phase IIb field-based clinical trial with Anergis’ lead compound AllerT for patients with birch pollen allergy.
Company News: Curetis’ Global Installed Base Expanding to Over 150 Unyvero Analyzers
– Completion of EMEA Direct Sales team build-out drives 46% growth in system installations over the course of 2016
– Reported unaudited FY 2016 revenue and strong year-end cash position
Curetis N.V. (Euronext: CURE, the “Company” and, together with Curetis GmbH, “Curetis”), a developer of next-level molecular diagnostic solutions, today announced the installation of its milestone 150th Unyvero Analyzer worldwide.
Company News: Anergis Appoints Klaus Schollmeier as New Chairman of the Board of Directors
– Senior Pharma and Biotech Executive joins Anergis´ Board of Directors as New Chairman
Anergis SA, a Swiss clinical-stage biopharmaceutical company developing proprietary products for ultra-fast allergy immunotherapy, today announced the appointment of Dr. Klaus Schollmeier as Chairman of its Board of Directors.